Why the study?
Coronary assessment is frequently performed in patients with sustained monomorphic ventricular tachycardia, but its yield and subsequent treatment implications remain unclear.
Does revascularisation improve time to ventricular tachycardia recurrence compared to medical management in patients presenting with acute sustained monomorphic ventricular tachycardia and significant coronary artery disease?
Cohort (n=249)
Does revascularisation improve time to ventricular tachycardia recurrence compared to medical management in patients presenting with acute sustained monomorphic ventricular tachycardia and significant coronary artery disease?
In patients presenting with sustained monomorphic ventricular tachycardia, coronary assessment has a modest yield for significant CAD, and revascularization alone does not appear to improve freedom from VT recurrence compared to medical management.
BACKGROUND: Coronary assessment is frequently conducted in patients with sustained monomorphic ventricular tachycardia (SMVT); however, its yield and subsequent treatment implications remain unclear. This study aimed to determine the prevalence of coronary artery disease (CAD) in patients presenting with SMVT, factors influencing clinician referral for coronary assessment, and clinical outcomes based on revascularisation or medical management of CAD. METHOD: Consecutive patients presenting with acute SMVT requiring inpatient admission between 2017 and 2022 were identified. RESULTS: A total of 249 individual patients with SMVT were identified, with 140 undergoing coronary assessment. Referral for coronary assessment was driven by chest pain (p<0.001) and increased troponin kinetics (p<0.001). No patient with SMVT had an acute coronary occlusion. Significant CAD was found in 48 (34%) patients, and traditional ischaemic features did not predict significant CAD. Nineteen (40%) patients with significant CAD underwent revascularisation (n=15 percutaneous coronary intervention, n=4 coronary artery bypass grafting). There was no significant difference in time to ventricular tachycardia (VT) recurrence between revascularised and medically managed CAD (hazard ratio 1.670; 95% confidence interval 0.756-3.687; p=0.199). A total of five of six patients who underwent a revascularisation-only strategy (no upfront antiarrhythmic therapy or ablation) had VT recurrence (median time to recurrence 8.9 months). CONCLUSIONS: Despite being frequently performed, coronary assessment in SMVT has only modest yield, with no patients having an acute coronary occlusion. Traditional clinical factors of ischaemia did not improve this yield. Revascularisation alone did not improve freedom from VT.
No takes yet. Share an insight, caveat, or question.
Bhaskaran et al. (2024) conducted a cohort in Sustained monomorphic ventricular tachycardia (n=249). Revascularisation vs. Medical management was evaluated on Time to ventricular tachycardia (VT) recurrence (HR 1.670, 95% CI 0.756-3.687, p=0.199).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: